Institute of Genomics and Integrative Biology (IGIB), constituent lab of CSIR, has signed a MoU with TATA Sons for licensing of KNOWHOW for FELUDA in order to execute rapid diagnosis of COVID-19. The MoU aims to provide license which will enable transfer of the knowledge for scaling up the KNOWHOW in the form of a kit in order to employ it for COVID-19 testing on ground as soon as possible. Hence, as per MoU, CSIR-IGIB will now work along with TATA Sons to bring FELUDA for widespread use at the earliest.
Click Here To Get Test Series For SBI PO 2020
FNCAS9 Editor Linked Uniform Detection Assay (FELUDA) has been designed to alleviate the current COVID-19 situation and cater to mass testing. The main advantages of FELUDA is its affordability, relative ease of use as well as non-dependency on expensive Q-PCR machines.
India's cities are often known not just by their original names but also by unique…
On May 5th, the world unites to celebrate the Portuguese language, a linguistic treasure that…
In a groundbreaking endeavor, China has launched the Chang'e-6 probe on an ambitious mission to…
Frank Shrontz, who led Boeing as its Chief Executive Officer for a decade from 1986…
Lando Norris of McLaren clinched his first-ever Grand Prix victory in a pulsating showdown at…
India, renowned for its rich cultural heritage and diverse landscapes, also boasts a thriving tea…